In Phase 2 cross-trial comparisons, retatrutide produced greater mean weight loss (~24% at 48 weeks) than published tirzepatide data (~2022% at 72 weeks)
This is particularly relevant for gut health applications, where the peptide needs to interact with the intestinal lining over an extended period
If swelling, severe pain, or pus develops, contact your healthcare provider right away
- The clinical indication for use (e.g., blood-brain barrier disruption, tumor, inflammation) - The MRI or diagnostic procedure associated with the contra,st including date and provider order - The time and route of administration (e.g., IV bolus), and any patient reactions or observations
BPC-157 is a signaling peptidea short chain of amino acids that promotes tissue repair and reduces inflammation
Door shelves experience significant temperature fluctuations every time you open the fridge